Guggenheim Reiterates Buy Rating on Bruker Corporation
Guggenheim maintains its optimistic view on Bruker with a $70 price target, a 16.32% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating for Bruker Corporation with a $70 price target on June 29, 2026.
- Guggenheim's $70 price target implies 16.32% upside from Bruker Corporation's ($BRKR) current $60.18 share price.
- Shares of NasdaqGS:BRKR traded near $60.91 on Monday, with a market cap of approximately $9.27 billion.
- Bruker insiders and analysts show varied activity, with insider buying and multiple firms maintaining ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim reiterated its buy rating on Bruker Corporation (NASDAQ: BRKR) on June 29, 2026, setting a price target of $70. Analyst Subbu Nambi affirmed the firm's positive outlook on the company, which specializes in scientific instruments and analytical solutions.
Bruker Corporation Stock Up 5.4%
Shares of Bruker Corporation traded near $60.91 on Monday, reflecting a market capitalization of about $9.27 billion. The company operates with a forward P/E ratio of 25.0 and a beta of 1.302, indicating moderate market volatility. Over the past 52 weeks, the stock has seen a low of $28.53 and a high of $64.54. Its 50-day moving average is $47.91, while the 200-day moving average stands at $42.55.
$BRKR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Bruker Corporation reported revenue of approximately $3.46 billion, showing a modest growth of 2.7%. However, the company is not currently profitable, with a negative net margin of -0.34% and a return on equity of -0.43%. The next earnings release is scheduled for August 4, 2026.
Dividend
Bruker offers an annual dividend rate of $0.20 per share, with a dividend yield of 0.33%. The payout ratio is relatively low at 38.5%, suggesting the company retains a significant portion of its earnings for reinvestment.
Insider Buying and Selling at Bruker Corporation
On June 15, 2026, Mark Munch, Executive VP and President of Bruker Nano Inc., sold 2,000 shares at an average price of $54.76 and purchased 2,000 shares at $22.19. Thierry Bernard also bought 2,886 shares on May 15, 2026.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim maintained its buy rating with a $70 price target. Barclays also maintained a buy rating with a $60 target on June 24, 2026. JP Morgan echoed the buy sentiment with a $65 target on June 8, 2026. The consensus recommendation is a buy, with an average target price of $53.83 among 12 analyst opinions.
About Bruker Corporation
Bruker Corporation, based in Billerica, Massachusetts, develops and distributes scientific instruments and analytical solutions. The company operates through several segments, including Bruker Scientific Instruments and Bruker Energy & Supercon Technologies. Its offerings include magnetic resonance spectroscopy, preclinical imaging, and life science tools. Founded in 1960, Bruker is led by CEO Dr. Frank H. Laukien and employs around 11,085 people.
Bottom Line
Guggenheim's reaffirmation of a buy rating on Bruker Corporation underscores continued confidence in the company's market position. While the stock has shown some volatility, it remains a focus for investors given its scientific instrumentation expertise. As always, it's important to remember that analyst ratings are just one piece of the puzzle, and investors should consider their own research before making decisions.
Get Bruker Corporation alerts
New 13F filings, insider trades, and analyst moves on $BRKR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.